VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain. The Dutch biotech has secured an exclusive option to evaluate ...
VectorY gains exclusive rights to evaluate and potentially license SHP-DB1, enhancing its neurodegenerative disease therapy pipeline. SHP-DB1, an engineered AAV5 capsid, offers improved brain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback